NNC0165-1875
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
Novo Nordisk · Phase 2 · Completed · Enrollment 120
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide 2.4 mg and NNC0165-1875 2.0 mg | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg) | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg and NNC0165-1875 1.0 mg | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg) | n/r | n/r | n/r | n/r |
Not shown
- Semaglutide 2.4 mg and NNC0165-1875 2.0 mg: endpoint not reported
- Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg): endpoint not reported
- Semaglutide 2.4 mg and NNC0165-1875 1.0 mg: endpoint not reported
- Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg): endpoint not reported